Subcutaneous Lecanemab: Potential Benefits and Place in Therapy

Abstract

Background: Lecanemab is a novel, humanized monoclonal antibody, which has demonstrated the ability to substantially reduce markers of amyloid and slow clinical decline on multiple measures of cognition and function in early Alzheimer’s disease (AD).

The paper